CAYMAN-FINANCE
17.11.2021 08:02:11 CET | Business Wire | Press release
Cayman Finance today is releasing a critical analysis of a new report by the Tax Justice Network, the State of Tax Justice 2021. TJN’s use of extremely distorted estimates and its failure to acknowledge the Cayman Islands’ tax neutrality and significant safeguards against tax evasion and aggressive tax avoidance have resulted in a report that is highly unreliable in its conclusions about the Cayman Islands financial services industry. As Cayman Finance research continues to demonstrate, TJN reports consistently lack credibility because of significant problems with their choice of data and application of methodology.
Cayman Finance’s new analytical report -- “TJN’s State of Tax Justice: A Critical Review ” – evaluates TJN’s State of Tax Justice Report for 2021 as well as the version previously released for 2020. Cayman Finance’s assessment was produced by noted economist Julian Morris and addresses both highly inaccurate estimates of corporate tax data as well as substantial errors in TJN’s reporting on the legal and regulatory environment in the Cayman Islands. Some criticisms of the Cayman Islands in the State of Tax Justice are recycled from TJN’s Financial Secrecy Index, which Cayman Finance dismantled in a previous report .
“The State of Tax Justice report continues the Tax Justice Network’s record of using distorted estimates and inaccurate assessments to reach highly unreliable conclusions about the Cayman Islands,” said Jude Scott, the CEO of Cayman Finance . “Cayman Finance has once again produced a careful analysis that relies on credible research to document TJN’s efforts to manipulate data to produce pre-determined results. TJN’s reports like the State of Tax Justice and the Financial Secrecy Index cannot be taken seriously unless TJN begins to use more accurate data and reliable assumptions – and Cayman Finance will continue to shine a bright light on their work until they do.”
Cayman Finance’s research determined that TJN’s State of Tax Justice 2021 is based on:
“Extremely distorted estimates” – One of TJN’s own founders, Richard Murphy, concedes that: a) TJN uses BIS data that does not differentiate personal and corporate deposits; b) TJN fails to recognise ‘that there may be commercial reasons for some of these deposits despite this referring to the fact in the methodology note’ and c) Offshore holding is not necessarily for the purposes of tax abuse.
“Similarly shaky premises ” – TJN’s “own metrics for Banking secrecy show that Cayman is not a secrecy jurisdiction. Indeed, Cayman’s verified beneficial ownership registry combined with its tax information exchange agreements strongly disincentivizes individuals from attempting to use the jurisdiction to engage in tax evasion.”
Julian Morris, leading economist and author of the Cayman Finance report, explains further: “TJN uses erroneous methods to derive estimates of tax avoidance and evasion. As a result, it wildly exaggerates the extent of avoidance and evasion facilitated by Cayman. As long as TJN continues to use such erroneous methods, the State of Tax Justice cannot be relied upon as a credible assessment of the Cayman Islands.”
Cayman Finance’s “TJN’s State of Tax Justice: A Critical Review” by Julian Morris, as well as analyses of other TJN reports, can be found at www.caymanfinance.ky .
About Cayman Finance:
Cayman Finance is the association of the financial services industry of the Cayman Islands, a premier global tax neutral financial hub efficiently connecting law abiding users and providers of investment capital and financing around the world. Cayman Finance represents first rate service providers within investment funds and asset management, banking, insurance, reinsurance, capital markets, and trusts sectors and world class fiduciary, legal, and public accounting service providers. Additionally, Cayman Finance represents 15 industry associations. Learn more at: www.caymanfinance.ky
View source version on businesswire.com: https://www.businesswire.com/news/home/20211116006475/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
FDA Issues Modified Risk Tobacco Product Orders for 20 ZYN Nicotine Pouch Products30.6.2026 18:19:00 CEST | Press release
FDA’s decision makes ZYN the first nicotine pouch product to receive MRTP orders authorizing reduced-risk claims versus cigarettes Philip Morris International Inc. (PMI) (NYSE: PM) today announced that the U.S. Food and Drug Administration (FDA) issued Modified Risk Tobacco Product (MRTP) orders for 20 variants of ZYN nicotine pouch products. These are the first MRTP orders granted for nicotine pouches, allowing PMI U.S. to market the following claim for the authorized ZYN products: “Using ZYN instead of cigarettes puts you at a lower risk of mouth cancer, heart disease, lung cancer, stroke, emphysema, and chronic bronchitis.” “FDA’s decision is an important moment for the more than 45 million legal-age nicotine consumers in America,” saidStacey Kennedy, PMI U.S. CEO. “Today’s news ensures these adultshave access to accurate, science-based information, including FDA-authorized evidence that switching from cigarettes to ZYN reduces the risk of smoking-related diseases like heart disease
Caidya Announces Strategic Combination with Simbec-Orion Bridging Early Scientific Insight and Global Clinical Execution30.6.2026 17:00:00 CEST | Press release
Caidya today announced a strategic combination with Simbec-Orion designed to close the divide between early scientific insight and global clinical execution. The combination of Caidya and Simbec-Orion creates a differentiated specialty clinical CRO platform that enables programs to scale, maintaining focus, speed, and accountability. The strategic combination brings together complementary strengths to create a more complete development partner for innovative biopharma companies. With established operations across Europe, the Americas, APAC, and China, the combined organization provides meaningful expertise and execution capabilities in the regions that matter most. Simbec-Orion brings early-phase clinical pharmacology capabilities alongside deep therapeutic expertise for later stage complex oncology and rare disease trials, helping sponsors shape critical decisions early in the development lifecycle. Together, the organizations strengthen their ability to support complex, cross-border
Archer® Proves Purpose-Built AI Beats General-Purpose LLMs on Regulatory Change Management: 95% Verified Accuracy, 80x Faster, 92% Lower Cost30.6.2026 16:13:00 CEST | Press release
In a head-to-head benchmark, a leading general-purpose LLM was confidently wrong 35% of the time on regulatory dates. Archer Evolv™ shipped zero errors. For enterprises deploying AI in compliance, a wrong date is a missed deadline. The more dangerous failure is a wrong answer the model returns with high confidence, one that flows silently into a compliance calendar and is only discovered after the window has passed. Archer® today released results showing purpose-built AI beats a general-purpose large language model (LLM) on regulatory work, and it’s not close. This head-to-head test compared Archer’s purpose-built, vertical-specific AI and proprietary data sets against a leading general-purpose LLM, on a core compliance task: determining the publication, effective and comment-close dates of regulatory documents across six jurisdictions. General-purpose models are a genuine breakthrough, and this is no referendum on their quality. The question Archer set out to answer is narrower and mo
Altasciences Supports Key Development Milestone for Steel Therapeutics’ Lead Therapeutic Candidate, Fizurex™30.6.2026 16:08:00 CEST | Press release
Altasciences, a leading drug development organization, today announced a significant milestone in the development of Steel Therapeutics, Inc.’s pivotal toxicology study for its lead product candidate, Fizurex™, for the treatment of anal fissures. The successful completion of the study plays a significant role in the advancement of Fizurex™ toward first-in-human trials. The GLP-compliant study demonstrated a favorable safety profile, which has advanced Steel Therapeutics' plans to submit an Investigational New Drug (IND) application for Fizurex™ to the FDA in Q3 2026. Fizurex™, a patent-pending, single-use topical wipe, was designed to provide a standardized, accessible treatment option for a painful and often undertreated medical condition. The product builds on years of use through compounding pharmacy prescriptions and is now advancing toward clinical development and regulatory review. "We are proud to have supported Steel Therapeutics with the generation of the high-quality safety d
Interactive Brokers Expands Access to Korean Equities with Launch of Nextrade ATS30.6.2026 16:00:00 CEST | Press release
IB SmartRouting℠ Routes Orders to the Best Available Price Between KRX and Nextrade Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced the launch of select Korean equities through Nextrade, South Korea's first Alternative Trading System (ATS). The addition of Nextrade builds on Interactive Brokers' earlier launch of the Korea Exchange (KRX), through which it became the first major US-based broker to provide global investors with direct access to Korean equities. Clients trading on Nextrade benefit from significantly extended trading hours and access to additional liquidity. Interactive Brokers has enabled IB SmartRouting℠ across both the Korea Exchange (KRX) and Nextrade, automatically routing orders to the venue offering the best price. This helps clients achieve best execution while providing greater flexibility and more opportunities to participate in one of Asia's most dynamic equity markets. Korea's equity market ranks among the top global exchanges by
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
